Research letter
Tofacitinib for cutaneous and pulmonary sarcoidosis: A case series

https://doi.org/10.1016/j.jaad.2020.10.016Get rights and content

First page preview

First page preview
Click to open first page preview

References (5)

There are more references available in the full text version of this article.

Cited by (21)

  • Cutaneous Sarcoidosis

    2024, Clinics in Chest Medicine
  • Anti-inflammatory Therapy for Sarcoidosis

    2024, Clinics in Chest Medicine
  • Quality of life in sarcoidosis

    2023, Journal of Autoimmunity
  • The CSF in neurosarcoidosis contains consistent clonal expansion of CD8 T cells, but not CD4 T cells

    2022, Journal of Neuroimmunology
    Citation Excerpt :

    These findings suggests that IFNγ-driven JAK/STAT signaling may play a central pathogenic role across multiple tissues in sarcoidosis. In support of this, multiple case reports or small case series have described the successful treatment of cutaneous, pulmonary, or multiorgan sarcoidosis with the JAK inhibitor tofacitinib or baricitinib (Alam et al., 2021; Damsky et al., 2018; Damsky et al., 2020; Friedman et al., 2021; Kerkemeyer et al., 2021; Scheinberg et al., 2020; Singh et al., 2021; Talty et al., 2021). Thus, JAK inhibitors may offer an additional treatment option to the current set of therapeutics by targeting IFN-signaling.

View all citing articles on Scopus

Funding sources: None.

Disclosure: Dr Sinclair holds patent/intellectual property no. US 62811353 entitled “Treatment of Autoimmune Disease.” Drs Kerkemeyer and Meah have no conflicts of interest to declare.

IRB approval status: Not applicable: retrospective design, patients treated during routine clinical practice (and not as part of a study involving subjects).

View full text